| Literature DB >> 33833794 |
Bingqi Ma1, Huijuan Meng2, An Shen1, Yuwen Ma1, Dianpeng Zhao1, Guiling Liu1, Shujuan Zheng1, Ye Tian3, Wei Zhang4, Qiang Li4, Shiping Li1.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is characterised by heterogeneity, and it can be subdivided into small-duct and large-duct types. Inflammatory and tumour markers could effectively predict prognosis in many cancers, but no similar studies have been conducted in the histological subtypes of ICC. A total of 102 and 72 patients with ICC undergoing curative-intent resection were retrospectively subclassified into large-duct and small-duct types by chemical staining, respectively. The prognostic value of inflammatory and tumour markers was studied for the first time in histological subtypes of ICC by using a Cox regression model. A novel predictor named prognostic inflammatory index (PII) was proposed and defined as neutrophil × monocyte/lymphocyte count (109/L). Survival analysis showed that PII, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA242, and ferritin were all predictors of DFS and OS in patients with ICC (P < 0.040). Subgroup analysis showed that PII, CA19-9, and ferritin were risk predictors of disease-free survival (DFS) and overall survival (OS) in small-duct type ICC (P < 0.015). In addition, in small-duct type ICC, NLR and LMR were correlated with OS (P < 0.025), whilst CEA and CA242 were correlated with DFS (P ≤ 0.010). In conclusion, PII is a convenient and efficient inflammatory predictor of DFS and OS in ICCs and their small-duct type. NLR and LMR, rather than platelet-to-lymphocyte ratio, were correlated with OS in small-duct type ICC. In addition, ferritin may be a supplement to CA19-9 in stratifying the survival outcome of patients with small-duct type ICC.Entities:
Year: 2021 PMID: 33833794 PMCID: PMC8018878 DOI: 10.1155/2021/6616062
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Univariate analysis of prognostic factors for ICC in the training cohort.
| Variables | DFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Platelet (10^9/L) | 1.450 | 0.758-2.776 | 0.262 | 0.750 | 0.367-1.535 | 0.431 |
| (<165 vs. ≥165) | ||||||
| Neutrophil (10^9/L) | 2.183 | 1.331-3.581 | 0.002 | 2.441 | 1.311-4.544 | 0.005 |
| (<4.15 vs. ≥4.15) | ||||||
| Lymphocyte (10^9/L) | 0.600 | 0.368-0.978 | 0.041 | 0.564 | 0.305-1.043 | 0.068 |
| (<1.60 vs. ≥1.60) | ||||||
| Monocyte (10^9/L) | 1.697 | 0.970-2.969 | 0.064 | 2.307 | 1.162-4.581 | 0.017 |
| (<0.54 vs. ≥0.54) | ||||||
| NLR | 2.081 | 1.156-3.747 | 0.015 | 2.698 | 1.338-5.442 | 0.006 |
| (<3.00 vs. ≥3.00) | ||||||
| LMR | 0.454 | 0.215-0.960 | 0.039 | 0.275 | 0.110-0.684 | 0.006 |
| (<2.70 vs. ≥2.70) | ||||||
| PLR | 1.851 | 0.987-3.474 | 0.055 | 0.910 | 0.456-1.817 | 0.789 |
| (<90.0 vs. ≥90.0) | ||||||
| CEA (ug/L) | 2.555 | 1.518-4.299 | ≤0.001 | 2.193 | 1.120-4.293 | 0.022 |
| (<4.50 vs. ≥4.50) | ||||||
| CA19-9 (U/ml) | 2.974 | 1.791-4.936 | ≤0.001 | 2.775 | 1.464-5.262 | 0.002 |
| (<76.0 vs. ≥76.0) | ||||||
| CA242 (IU/ml) | 2.976 | 1.688-5.247 | ≤0.001 | 2.511 | 1.235-5.106 | 0.011 |
| (<30.0 vs. ≥30.0) | ||||||
| Ferritin (ug/L) | 2.495 | 1.372-4.538 | 0.003 | 3.761 | 1.650-8.572 | 0.002 |
| (<150.0 vs. ≥150.0) | ||||||
| PII | 2.685 | 1.498-4.812 | 0.001 | 3.161 | 1.628-6.138 | 0.001 |
| (<1.50 vs. ≥1.50) | ||||||
Figure 1Survival analysis showing patients with high PII had poor prognosis in ICCs (a) and (b) and their small-duct type (c) and (d).
Figure 2Survival analysis showing patients with high CA19-9 had poor prognosis in ICCs (a) and (b) and their small-duct type (c) and (d).
Figure 3Survival analysis showing patients with high ferritin had poor prognosis in ICCs (a) and (b) and their small-duct type (c) and (d).
Multivariate analysis of prognostic factors for ICC in the training cohort.
| Variables | DFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Inflammatory factors | ||||||
| Neutrophil (10^9/L) | 1.791 | 1.063-3.017 | 0.029 | 2.098 | 1.095-4.019 | 0.025 |
| (<4.15 vs. ≥4.15) | ||||||
| Lymphocyte (10^9/L) | 0.594 | 0.332-1.061 | 0.078 | |||
| (<1.60 vs. ≥1.60) | ||||||
| Monocyte (10^9/L) | 2.042 | 0.884-4.714 | 0.095 | |||
| (<0.54 vs. ≥0.54) | ||||||
| NLR | 1.554 | 0.801-3.013 | 0.192 | 2.117 | 0.944-4.748 | 0.069 |
| (<3.00 vs. ≥3.00) | ||||||
| LMR | 0.772 | 0.339-1.758 | 0.537 | 0.367 | 0.136-0.993 | 0.048 |
| (<2.70 vs. ≥2.70) | ||||||
| PII | 1.904 | 1.017-3.563 | 0.044 | 3.360 | 1.604-7.038 | 0.001 |
| (<1.50 vs. ≥1.50) | ||||||
| Tumour markers | ||||||
| CEA (ug/L) | 2.414 | 1.383-4.214 | 0.002 | 1.851 | 0.856-4.001 | 0.118 |
| (<4.50 vs. ≥4.50) | ||||||
| CA19-9 (U/ml) | 2.934 | 1.696-5.074 | ≤0.001 | 3.358 | 1.668-6.760 | 0.001 |
| (<76.0 vs. ≥76.0) | ||||||
| CA242 (IU/ml) | 2.737 | 1.488-5.036 | 0.001 | 2.348 | 1.103-5.001 | 0.027 |
| (<30.0 vs. ≥30.0) | ||||||
| Ferritin (ug/L) | 2.534 | 1.352-4.750 | 0.004 | 3.779 | 1.590-9.077 | 0.003 |
| (<150.0 vs. ≥150.0) | ||||||
Univariate analysis of prognostic factors for small-duct type ICC in the training cohort.
| Variables | DFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Platelet (10^9/L) | 1.185 | 0.574-2.447 | 0.646 | 0.646 | 0.287-1.455 | 0.292 |
| (<165 vs. ≥165) | ||||||
| Neutrophil (10^9/L) | 2.033 | 1.143-3.576 | 0.015 | 1.976 | 0.954-4.090 | 0.067 |
| (<4.15 vs. ≥4.15) | ||||||
| Lymphocyte (10^9/L) | 0.495 | 0.281-0.872 | 0.015 | 0.476 | 0.231-0.982 | 0.044 |
| (<1.60 vs. ≥1.60) | ||||||
| Monocyte (10^9/L) | 1.061 | 4.495-2.273 | 0.878 | 1.496 | 0.567-3.949 | 0.416 |
| (<0.54 vs. ≥0.54) | ||||||
| NLR | 1.877 | 0.949-3.714 | 0.071 | 2.642 | 1.161-6.019 | 0.021 |
| (<3.00 vs. ≥3.00) | ||||||
| LMR | 0.394 | 0.152-1.021 | 0.055 | 0.218 | 0.070 | 0.008 |
| (<2.70 vs. ≥2.70) | ||||||
| PLR | 1.791 | 0.889-3.608 | 0.103 | 0.862 | 0.395-1.883 | 0.710 |
| (<90.0 vs. ≥90.0) | ||||||
| PII | 2.367 | 1.186-4.724 | 0.014 | 3.127 | 1.420-6.886 | 0.005 |
| (<1.50 vs. ≥1.50) | ||||||
| CEA (ug/L) | 2.383 | 1.229-4.619 | 0.010 | 1.731 | 0.698-4.292 | 0.236 |
| (<4.50 vs. ≥4.50) | ||||||
| CA19-9 (U/ml) | 2.956 | 1.586-5.508 | 0.001 | 2.858 | 1.287-6.347 | 0.010 |
| (<76.0 vs. ≥76.0) | ||||||
| CA242 (IU/ml) | 3.254 | 1.544-6.859 | 0.002 | 2.073 | 0.779-5.516 | 0.145 |
| (<30.0 vs. ≥30.0) | ||||||
| Ferritin (ug/L) | 2.466 | 1.270 | 0.008 | 4.391 | 1.658-11.629 | 0.003 |
| (<150.0 vs. ≥150.0) | ||||||
Multivariate analysis of prognostic factors for small-duct type ICC in the training cohort.
| Variables | DFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Inflammatory factors | ||||||
| Neutrophil (10^9/L) | 1.498 | 0.801-2.801 | 0.206 | |||
| (<4.15 vs. ≥4.15) | ||||||
| Lymphocyte (10^9/L) | 0.450 | 0.232-0.870 | 0.018 | 0.495 | 0.217-1.131 | 0.095 |
| (<1.60 vs. ≥1.60) | ||||||
| NLR | 1.666 | 0.543-5.110 | 0.372 | |||
| (<3.00 vs. ≥3.00) | ||||||
| LMR | 0.250 | 0.071-0.882 | 0.031 | |||
| (<2.70 vs. ≥2.70) | ||||||
| PII | 1.674 | 0.792-3.540 | 0.177 | 3.215 | 1.350-7.655 | 0.008 |
| (<1.50 vs. ≥1.50) | ||||||
| Tumour markers | ||||||
| CEA (ug/L) | 2.583 | 1.251-5.334 | 0.010 | |||
| (<4.50 vs. ≥4.50) | ||||||
| CA19-9 (U/ml) | 2.946 | 1.442-6.020 | 0.003 | 3.792 | 1.542-9.327 | 0.004 |
| (<76.0 vs. ≥76.0) | ||||||
| CA242 (IU/ml) | 2.988 | 1.287-6.938 | 0.011 | |||
| (<30.0 vs. ≥30.0) | ||||||
| Ferritin (ug/L) | 2.052 | 0.987-4.265 | 0.054 | 2.903 | 1.037-8.127 | 0.042 |
| (<150.0 vs. ≥150.0) | ||||||
Association of PII and ferritin with demographic and clinicopathological characteristics in small-duct type ICC of training cohort.
| Variables | PII | Ferritin | ||||
|---|---|---|---|---|---|---|
| Low | High |
| Low | High |
| |
| Age (years) | 0.289 | 0.032 | ||||
| <65 | 52 (81.3%) | 12 (18.8%) | 16 (27.6%) | 42 (72.4%) | ||
| ≥65 | 15 (93.8%) | 1 (6.3%) | 9 (56.3%) | 7 (43.8%) | ||
| Gender | 0.711 | 0.015 | ||||
| Male | 39 (84.8%) | 7 (15.2%) | 10 (22.7%) | 34 (77.3%) | ||
| Female | 28 (82.4%) | 6 (17.6%) | 15 (50.0%) | 15 (50.0%) | ||
| INR | 0.025 | 0.026 | ||||
| <1.0 | 43 (91.5%) | 4 (8.5%) | 19 (44.2%) | 24 (55.8%) | ||
| ≥1.0 | 24 (72.7%) | 9 (27.3%) | 6 (19.4%) | 25 (80.6%) | ||
| ALT (U/L) | 0.069 | 0.019 | ||||
| <40 | 54 (88.5%) | 7 (11.5%) | 23 (41.1%) | 33 (58.9%) | ||
| ≥40 | 13 (68.4%) | 6 (31.6%) | 2 (11.1%) | 16 (88.9%) | ||
| Albumin (g/L) | 0.115 | 0.279 | ||||
| <43 | 20 (74.1%) | 7 (25.9%) | 7 (25.9%) | 20 (74.1%) | ||
| ≥43 | 47 (88.7%) | 6 (11.3%) | 18 (38.3%) | 29 (61.7%) | ||
| TBIL (umol/L) | 0.052 | 0.024 | ||||
| <21 | 61 (87.1%) | 9 (12.9%) | 25 (38.5%) | 40 (61.5%) | ||
| ≥21 | 6 (60.0%) | 4 (40.0%) | 0 (0.0%) | 9 (100.0%) | ||
| GGT (U/L) | 0.043 | 0.001 | ||||
| <45 | 36 (92.3%) | 3 (7.7%) | 19 (52.8%) | 17 (47.2%) | ||
| ≥45 | 31 (75.6%) | 10 (24.4%) | 6 (15.8%) | 32 (84.2%) | ||
| ALP (U/L) | 0.005 | 0.197 | ||||
| <135 | 60 (89.6%) | 7 (10.4%) | 19 (52.8%) | 17 (47.2%) | ||
| ≥135 | 7 (53.8%) | 6 (46.2%) | 6 (15.8%) | 32 (84.2%) | ||
| Histological grade | 0.328 | 0.254 | ||||
| G1-G2 | 36 (80.0%) | 9 (20.0%) | 16 (40.0%) | 24 (60.0%) | ||
| G3 | 30 (88.2%) | 4 (11.8%) | 9 (27.3%) | 24 (72.7%) | ||
| Vascular invasion | 0.011 | 0.293 | ||||
| Negative | 40 (93.0%) | 3 (7.0%) | 16 (40.0%) | 24 (60.0%) | ||
| Positive | 25 (71.4%) | 10 (28.6%) | 9 (28.1%) | 23 (71.9%) | ||
| Satellite lesions | 1.000 | 0.411 | ||||
| Negative | 59 (83.1%) | 12 (16.9%) | 24 (35.8%) | 43 (64.2%) | ||
| Positive | 8 (88.9%) | 1 (11.1%) | 1 (14.3%) | 6 (85.7%) | ||
|
| 0.015 | 0.040 | ||||
| | 35 (94.6%) | 2 (5.4%) | 16 (45.7%) | 19 (54.3%) | ||
| | 32 (74.4%) | 11 (25.6%) | 9 (23.1%) | 30 (76.9%) | ||
|
| 1.000 | 0.119 | ||||
| | 23 (76.7%) | 7 (23.3%) | 12 (42.9%) | 16 (57.1%) | ||
| | 7 (77.8%) | 2 (22.2%) | 1 (11.1%) | 8 (88.9%) | ||
|
| 0.417 | 0.320 | ||||
| | 65 (84.4%) | 12 (15.6%) | 25 (35.2%) | 46 (64.8%) | ||
| | 2 (66.7%) | 1 (33.3%) | 0 (0.0%) | 3 (100.0%) | ||
| TNM stage | 0.669 | 0.065 | ||||
| I-II | 23 (79.3%) | 6 (20.7%) | 12 (44.4%) | 15 (55.6%) | ||
| III-IV | 7 (70.0%) | 3 (30.0%) | 1 (10.0%) | 9 (90.0%) | ||